Cholera Control by Case-area Targeted Interventions (CATIs)
Case-area Targeted Interventions (CATIs) Among Household Contacts and Neighbouring Households After Defining Cholera Hotspot Areas in Bangladesh: The Effectiveness of OCV and Potential Impact on Cholera Control
International Centre for Diarrhoeal Disease Research, Bangladesh
68,400 participants
Sep 5, 2024
INTERVENTIONAL
Conditions
Summary
To evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V. cholerae antigen from different hotspots in Dhaka city, cholera cases will be enrolled by rapid diagnostic test (RDT) from the diarrhoeal patients coming to icddr,b Dhaka hospital. Hotspots will be defined as the households (HHs) surrounding the RDT-positive cholera case (around 20-40m radius). The 'Case area targeted interventions' (CATI) will be given by administrating Oral Cholera Vaccine (OCV) with either one dose or two doses of OCV 1 month apart among household contacts (≥1-year age and non-pregnant women) and contacts of the contacts residing in the adjacent HHs. The passive surveillance for cholera will be followed using the icddr,b hospital, and other health facilities. Data on each individual's states of the clusters (e.g., susceptible, exposed, infectious, or recovered) will be tracked throughout the 3 years study follow-up.
Eligibility
Inclusion Criteria6
- Index case eligibility
- Some to severe dehydrated diarrheal patient
- Provide signed informed consent form
- Aged ≥1 year and non-pregnant
- Meeting the definition of IHC and NHC
- Provide signed informed consent form
Exclusion Criteria7
- \. Resident in a ward already covered by OCV since 2015
- Vaccination Eligibility
- History of taking OCV
- Currently suffering from diarrhea
- < 1 year of age
- Pregnant women (verbally confirmed)
- Index case
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Produced in Bangladesh and Licenced by the Directorate of Drug Administration (DGDA) for use in Bangladesh
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07685574